Boston Scientific Corporation (BSX) Shares Bought by Advisor Group Inc.
Advisor Group Inc. boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 67.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 24,552 shares of the medical equipment provider’s stock after buying an additional 9,853 shares during the period. Advisor Group Inc.’s holdings in Boston Scientific Corporation were worth $680,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC boosted its holdings in shares of Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock valued at $4,593,698,000 after buying an additional 13,105,596 shares during the period. BlackRock Inc. increased its position in shares of Boston Scientific Corporation by 4.6% during the second quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after acquiring an additional 4,439,966 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Boston Scientific Corporation by 2.8% during the second quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after acquiring an additional 2,522,556 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Boston Scientific Corporation by 7.9% during the first quarter. Geode Capital Management LLC now owns 12,120,374 shares of the medical equipment provider’s stock worth $300,963,000 after acquiring an additional 888,331 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Boston Scientific Corporation by 405.3% during the second quarter. Jennison Associates LLC now owns 10,639,290 shares of the medical equipment provider’s stock worth $294,921,000 after acquiring an additional 8,533,655 shares in the last quarter. 90.44% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on BSX shares. BidaskClub lowered shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research note on Saturday, August 26th. Stifel Nicolaus increased their target price on Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “hold” rating in a report on Wednesday, June 28th. Oppenheimer Holdings, Inc. set a $29.00 price target on Boston Scientific Corporation and gave the company a “hold” rating in a research note on Friday, July 28th. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research note on Friday, September 1st. Finally, Zacks Investment Research lowered Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $30.12.
WARNING: “Boston Scientific Corporation (BSX) Shares Bought by Advisor Group Inc.” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/04/boston-scientific-corporation-bsx-shares-bought-by-advisor-group-inc.html.
Shares of Boston Scientific Corporation (NYSE BSX) opened at 29.02 on Wednesday. The stock has a 50 day moving average of $28.06 and a 200-day moving average of $26.92. The company has a market capitalization of $39.82 billion, a PE ratio of 51.91 and a beta of 1.09. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.50.
Boston Scientific Corporation (NYSE:BSX) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the previous year, the firm earned $0.27 earnings per share. Boston Scientific Corporation’s quarterly revenue was up 6.2% on a year-over-year basis. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.
In other news, SVP Wendy Carruthers sold 12,433 shares of the company’s stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total value of $332,582.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders sold a total of 276,318 shares of company stock valued at $7,567,967 over the last three months. 0.74% of the stock is currently owned by insiders.
Boston Scientific Corporation Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).
Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.